References
- American Diabetes Association. Clinical Practice Recommendations. Diabetes Care 36(Suppl. 1) (2013).
- Bailey CJ. Metformin–an update. Gen. Pharmacol. 24(6), 1299–1309 (1993).
- Glueck CJ, Fontaine RN, Wang P et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 50(7), 856–861 (2001).
- Powers AC, D’Alessio D. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics (12th Edition). Brunton L, Chabner B, Knollman B (Eds). McGraw Hill Medical, USA 1237–1274 (2011).
- Mu J, Petrov A, Eierman GJ et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol. 623(1–3), 148–154 (2009).
- Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical. Nat. Rev. Endocrinol. 8(8), 495–502 (2012).
- Mancini AD, Poitout V. The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol. Metab. 24(8), 398–407 (2013).
- Suter SL, Nolan JJ, Wallace P et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15(2), 193–203 (1992).
- Kolterman OG, Gray RS, Griffin J et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J. Clin. Invest. 68(4), 957–969 (1981).
- Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 54, 1150–1156 (2005).
- Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517–522 (2006).
- Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368, 1096–1105 (2006).
- Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006).
- Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes. Metab. 11(12), 1091–1099 (2009).
- Zander M, Christiansen A, Madsbad S, Holst JJ. Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 27(8), 1910–1914 (2004).
- Avruch J. Insulin signal transduction through protein kinase cascades. Mol. Cell. Biochem. 182(1–2), 31–48 (1998).
- Sugii S, Olson P, Sears DD et al. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl Acad. Sci. USA 106(52), 22504–22509 (2009).
- Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289–312 (2008).
- Chen Z, Vigueira PA, Chambers KT et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J. Biol. Chem. 287(28), 23537–23548 (2012).
Website
- International Diabetes Federation. www.idf.org/